Market Cap 30.18M
Revenue (ttm) 0.00
Net Income (ttm) -9.51M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,700
Avg Vol 3,858
Day's Range N/A - N/A
Shares Out 3.99M
Stochastic %K 77%
Beta 0.15
Analysts Strong Sell
Price Target $37.50

Company Profile

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab plus balstilim...

Industry: Biotechnology
Sector: Healthcare
Phone: 212 994 8250
Address:
149 Fifth Avenue, Suite 500, New York, United States
Biotechguy21
Biotechguy21 Jun. 16 at 8:38 PM
$AGEN $PTIX and don’t forget the other pos $INKT which is down 93% all time. Now look deeper into these and the stories are really interesting πŸ‘€πŸ‘€πŸ˜‚πŸ˜‚πŸ€‘πŸ€‘
0 Β· Reply
Biotechguy21
Biotechguy21 Jun. 12 at 3:46 PM
$AGEN $PTIX $INKT what a great list of stocks πŸ˜‚πŸ˜‚πŸ˜‚πŸ˜‚πŸ˜‚
0 Β· Reply
Biotechguy21
Biotechguy21 Jun. 8 at 10:40 PM
$PTIX $AGEN $INKT look deep into these pos stocks. easiest money ever. πŸ€‘πŸ€‘πŸ˜‚πŸ˜‚
0 Β· Reply
Biotechguy21
Biotechguy21 Jun. 4 at 11:39 PM
$AGEN congrats on this it’s only down 96.5% all the time. Same ceo. Same board. Same pos stock. Just like $INKT. What will be the excuse this time? πŸ€‘πŸ€‘πŸ€‘πŸ˜‚πŸ˜‚πŸ˜‚
0 Β· Reply
Slapshot22
Slapshot22 Jun. 4 at 7:26 PM
$INKT MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients Nice to pull some non-dilutive funding. Sort of recognizes the work being done. Good quote: β€œThis non-dilutive funding from NIAID underscores the growing recognition of iNKT cells as a unique and powerful modality in immune regulation,” said Jennifer Buell, PhD, President and Chief Executive Officer of MiNK Therapeutics. "This award both validates the promise of our iNKT platform and accelerates its development in a high-priority area of unmet medical need." Figured someone should post this. https://investor.minktherapeutics.com/news-releases/news-release-details/mink-therapeutics-awarded-prestigious-niaid-grant-advance-allo
0 Β· Reply
weichsel1
weichsel1 Jun. 4 at 3:02 AM
$AGEN With a market cap of 150m, and 90m cash on hand from the transaction on June 3rd ( which is at least 18 months of cash burn), the value of the Agenus drugs is only a net 60m. Presuming 30m shares outstanding and 5 dollar a share. Still rather undervalued, and this does not count the value of the interest in $INKT ( majority owned by Agenus).
0 Β· Reply
Biotechguy21
Biotechguy21 May. 21 at 12:42 AM
$AGEN $INKT two worthless stocks. same team = same failures
1 Β· Reply
2_logs_higher
2_logs_higher May. 16 at 12:50 PM
$AGEN & $INKT Amazing the PR dept does not work for Mink either. MiNK Therapeutics (NASDAQ: INKT) reported its Q1 2025 financial results and clinical progress. The company achieved a significant breakthrough with a complete remission in testicular cancer using a single infusion of agenT-797. Clinical trials are advancing, including an active Phase 2 trial in gastric cancer at Memorial Sloan Kettering. The company presented promising data showing agenT-797's effectiveness in PD-1-resistant gastroesophageal cancers. MiNK is pursuing strategic partnerships in oncology, immunology, and engineered cell therapies. Financially, Q1 2025 ended with $3.2 million cash, reduced cash burn to $1.3 million (vs $2.5M in Q1 2024), and a net loss of $2.8 million ($0.70 per share). The company expects NIAID funding for its GvHD program by June 2025. https://www.stocktitan.net/news/INKT/
1 Β· Reply
Biotechguy21
Biotechguy21 May. 6 at 9:38 AM
$AGEN $PTIX $INKT pos stocks. Look into them and do some research. πŸ‘€πŸ‘€πŸ€‘πŸ€‘
0 Β· Reply
Biotechguy21
Biotechguy21 May. 1 at 1:32 PM
$INKT pos stock just like $AGEN πŸ‘€πŸ‘€πŸ€‘πŸ€‘
0 Β· Reply
Latest News on INKT
MiNK Therapeutics, Inc. (INKT) Q1 2025 Earnings Call Transcript

May 15, 2025, 1:21 PM EDT - 4 weeks ago

MiNK Therapeutics, Inc. (INKT) Q1 2025 Earnings Call Transcript


MiNK Therapeutics, Inc. (INKT) Q4 2024 Earnings Call Transcript

Mar 18, 2025, 11:28 AM EDT - 3 months ago

MiNK Therapeutics, Inc. (INKT) Q4 2024 Earnings Call Transcript


MiNK Therapeutics, Inc. (INKT) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 2:51 PM EDT - 11 months ago

MiNK Therapeutics, Inc. (INKT) Q2 2024 Earnings Call Transcript


MiNK Reports Second Quarter 2024 Results and Business Update

Aug 13, 2024, 7:00 AM EDT - 11 months ago

MiNK Reports Second Quarter 2024 Results and Business Update


MiNK Therapeutics, Inc. (INKT) Q1 2024 Earnings Call Transcript

May 14, 2024, 11:07 AM EDT - 1 year ago

MiNK Therapeutics, Inc. (INKT) Q1 2024 Earnings Call Transcript


MiNK Reports First Quarter 2024 Results

May 14, 2024, 7:30 AM EDT - 1 year ago

MiNK Reports First Quarter 2024 Results


MiNK Reports Fourth Quarter and Year-End 2023 Results

Mar 21, 2024, 7:00 AM EDT - 1 year ago

MiNK Reports Fourth Quarter and Year-End 2023 Results


MiNK Therapeutics Reports Third Quarter 2023 Results

Nov 9, 2023, 7:00 AM EST - 1 year ago

MiNK Therapeutics Reports Third Quarter 2023 Results


MiNK Therapeutics Reports Second Quarter 2023 Results

Aug 10, 2023, 7:30 AM EDT - 2 years ago

MiNK Therapeutics Reports Second Quarter 2023 Results


MiNK's Novel FAP-CAR-iNKT Presented at ASGCT

May 18, 2023, 8:30 AM EDT - 2 years ago

MiNK's Novel FAP-CAR-iNKT Presented at ASGCT


MiNK Therapeutics, Inc. (INKT) Q1 2023 Earnings Call Transcript

May 14, 2023, 2:25 PM EDT - 2 years ago

MiNK Therapeutics, Inc. (INKT) Q1 2023 Earnings Call Transcript


MiNK Therapeutics, Inc. (INKT) Q4 2022 Earnings Call Transcript

Mar 21, 2023, 12:26 PM EDT - 2 years ago

MiNK Therapeutics, Inc. (INKT) Q4 2022 Earnings Call Transcript


Biotechguy21
Biotechguy21 Jun. 16 at 8:38 PM
$AGEN $PTIX and don’t forget the other pos $INKT which is down 93% all time. Now look deeper into these and the stories are really interesting πŸ‘€πŸ‘€πŸ˜‚πŸ˜‚πŸ€‘πŸ€‘
0 Β· Reply
Biotechguy21
Biotechguy21 Jun. 12 at 3:46 PM
$AGEN $PTIX $INKT what a great list of stocks πŸ˜‚πŸ˜‚πŸ˜‚πŸ˜‚πŸ˜‚
0 Β· Reply
Biotechguy21
Biotechguy21 Jun. 8 at 10:40 PM
$PTIX $AGEN $INKT look deep into these pos stocks. easiest money ever. πŸ€‘πŸ€‘πŸ˜‚πŸ˜‚
0 Β· Reply
Biotechguy21
Biotechguy21 Jun. 4 at 11:39 PM
$AGEN congrats on this it’s only down 96.5% all the time. Same ceo. Same board. Same pos stock. Just like $INKT. What will be the excuse this time? πŸ€‘πŸ€‘πŸ€‘πŸ˜‚πŸ˜‚πŸ˜‚
0 Β· Reply
Slapshot22
Slapshot22 Jun. 4 at 7:26 PM
$INKT MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients Nice to pull some non-dilutive funding. Sort of recognizes the work being done. Good quote: β€œThis non-dilutive funding from NIAID underscores the growing recognition of iNKT cells as a unique and powerful modality in immune regulation,” said Jennifer Buell, PhD, President and Chief Executive Officer of MiNK Therapeutics. "This award both validates the promise of our iNKT platform and accelerates its development in a high-priority area of unmet medical need." Figured someone should post this. https://investor.minktherapeutics.com/news-releases/news-release-details/mink-therapeutics-awarded-prestigious-niaid-grant-advance-allo
0 Β· Reply
weichsel1
weichsel1 Jun. 4 at 3:02 AM
$AGEN With a market cap of 150m, and 90m cash on hand from the transaction on June 3rd ( which is at least 18 months of cash burn), the value of the Agenus drugs is only a net 60m. Presuming 30m shares outstanding and 5 dollar a share. Still rather undervalued, and this does not count the value of the interest in $INKT ( majority owned by Agenus).
0 Β· Reply
Biotechguy21
Biotechguy21 May. 21 at 12:42 AM
$AGEN $INKT two worthless stocks. same team = same failures
1 Β· Reply
2_logs_higher
2_logs_higher May. 16 at 12:50 PM
$AGEN & $INKT Amazing the PR dept does not work for Mink either. MiNK Therapeutics (NASDAQ: INKT) reported its Q1 2025 financial results and clinical progress. The company achieved a significant breakthrough with a complete remission in testicular cancer using a single infusion of agenT-797. Clinical trials are advancing, including an active Phase 2 trial in gastric cancer at Memorial Sloan Kettering. The company presented promising data showing agenT-797's effectiveness in PD-1-resistant gastroesophageal cancers. MiNK is pursuing strategic partnerships in oncology, immunology, and engineered cell therapies. Financially, Q1 2025 ended with $3.2 million cash, reduced cash burn to $1.3 million (vs $2.5M in Q1 2024), and a net loss of $2.8 million ($0.70 per share). The company expects NIAID funding for its GvHD program by June 2025. https://www.stocktitan.net/news/INKT/
1 Β· Reply
Biotechguy21
Biotechguy21 May. 6 at 9:38 AM
$AGEN $PTIX $INKT pos stocks. Look into them and do some research. πŸ‘€πŸ‘€πŸ€‘πŸ€‘
0 Β· Reply
Biotechguy21
Biotechguy21 May. 1 at 1:32 PM
$INKT pos stock just like $AGEN πŸ‘€πŸ‘€πŸ€‘πŸ€‘
0 Β· Reply
TruthTooPower
TruthTooPower Apr. 30 at 11:51 AM
$INKT !!! We Are The Bomb Baby!!!
1 Β· Reply
Biotechguy21
Biotechguy21 Apr. 29 at 11:01 AM
$PTIX $AGEN $INKT well well what do we have here? Three POS stocks. πŸ‘€πŸ‘€πŸ‘€πŸ‘€πŸ‘€πŸ€‘πŸ€‘πŸ€‘πŸ€‘πŸ€‘πŸ”₯πŸ”₯πŸ”₯πŸ”₯
1 Β· Reply
Biotechguy21
Biotechguy21 Apr. 21 at 11:38 AM
$AGEN $PTIX $INKT look at these three and what do you see???? all loser stocks! And look deeper πŸ˜‚πŸ˜‚πŸ€‘πŸ€‘πŸ˜‚πŸ˜‚πŸ€‘πŸ€‘
0 Β· Reply
Marinshell
Marinshell Apr. 14 at 4:34 PM
$INKT what does Mink have to do with being a guest at tomorrow’s IBRX investor day announcements??? Cannot wait to hear.
0 Β· Reply
Biotechguy21
Biotechguy21 Apr. 10 at 12:14 PM
$AGEN $PTIX $INKT why do all three of these stocks suck so bad? πŸ€‘πŸ€‘πŸ˜‚πŸ˜‚πŸ‘€πŸ‘€
0 Β· Reply
PhoenixLights
PhoenixLights Apr. 8 at 6:53 PM
$IBRX $INKT $ONC seems curious to invite Dr. Mark Lanasa, Senior Vice President, Chief Medical Officer, Solid Tumors, BeiGene, and Dr. Jennifer Buell, President & Chief Executive Officer, MiNK Therapeutics, to ImmunityBio's first ever investors relations day. Perhaps that is common in the Biotech world. https://immunitybio.com/immunitybio-to-host-key-opinion-leader-and-investor-meeting-to-provide-updates-on-clinical-programs-and-anktiva-commercial-launch/
2 Β· Reply
BixbyKnolls
BixbyKnolls Apr. 8 at 5:38 PM
$IBRX What deal are we doing with $INKT - Mink Therapeutics? One of the speakers next week.
1 Β· Reply
Slapshot22
Slapshot22 Apr. 8 at 2:16 AM
$INKT Stock defines under the radar for me. Always amazed, see a % change, then pull up the volume: 4,520 shares today. Yeap, 4.5K shares is what it says. right around $36K if my math works out. I could move the stock price myself with a decent buy or sell order. Someday this stock may get into the light of day, but for now ... lotto ticket sitting on the back burner ... with not enough liquidity to do anything if you wanted. But, someday it may go mainstream. JMHO.
0 Β· Reply
Biotechguy21
Biotechguy21 Apr. 3 at 9:51 PM
$AGEN $INKT this pooor guy is still holding and losing every dime on these pos stocks. Terrible investing 🀑🀑🀑🀑🀑
0 Β· Reply
2_logs_higher
2_logs_higher Apr. 3 at 5:48 PM
$AGEN + $INKT Another TIGIT trial fails as BeiGene scraps Phase 3 drug good for inkt. https://endpts.com/another-tigit-trial-fails-as-beigene-scraps-phase-3-drug/
2 Β· Reply
Cs1992
Cs1992 Apr. 2 at 9:00 AM
$INKT 18 dollar soon
0 Β· Reply
Cs1992
Cs1992 Apr. 1 at 11:27 AM
0 Β· Reply